This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Premier Biomedical Announces Potential Therapy For Currently Untreatable Neurofibromatosis

ST. PETERSBURG, Fla., Jan. 9, 2013 /PRNewswire/ --  Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a proposed novel therapy for the treatment of the currently untreatable neurological condition Neurofibromatosis. The key to this breakthrough is the targeted application of the Felder Doctrine™, which calls for "physically removing the pathophysiologic basis of the disease."

The painful and often fatal disease Neurofibromatosis, which is characterized by the growth of tumors around nerves, appears in three classifications, with type 1 Neurofibromatosis affecting about 1 in 3,500 individuals worldwide. By processing the blood feeding the neurofibromas and by physically removing inflammatory cytokines and other molecular compounds responsible for the etiology of the disease, Premier Biomedical's Chairman of the Scientific Advisory Board Mitchell S. Felder, M.D., a board certified attending neurologist, believes that it is possible to stop the progression of the disease.

Premier Biomedical's CEO William A. Hartman emphasized, "At present, this is a hopeless disease, and to date, there has not been even a possibility of treatment. By applying for a provisional patent application, we are making the first step in our attempt to beat Neurofibromatosis. This potential breakthrough follows our other recent successes in applying the Felder Doctrine to cancer, clinical depression and suicidal ideation."

The news of this announcement follows Premier Biomedicals other recent applications of the Felder Doctrine, which include: killing a cancer tumor in a test tube within 24 hours by simply processing its environment, removing a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy, and successfully removing the majority of target antigens associated with clinical depression and suicidal ideation from a heterogeneous mixture, also at a picogram level of accuracy.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/ Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."  www.premierbiomedicalinc.com

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs